Condition

Metastatic Urothelial Carcinoma

ClinicalTrials.gov condition label

Clinical trials18

Recruiting6

Common interventions25

Lead sponsors shown11

Clinical trials

18 shown

Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLCNCT07671092 · 2026-06-15

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) ProgramNCT06265285 · 2024-04-30

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid TumorsNCT05733000 · 2023-03-08

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid TumorsNCT05269381 · 2022-03-31

A Study of NX-1607 in Adults With Advanced MalignanciesNCT05107674 · 2021-09-29

Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME TrialNCT04693377 · 2021-03-16

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO TrialNCT07576725 · 2026-12-01

NOT_YET_RECRUITING

A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)NCT06483334 · 2024-07-17

ACTIVE_NOT_RECRUITING

Study of OB-002 in Patients With Refractory Metastatic CancerNCT05940844 · 2024-01-01

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVNCT04514484 · 2021-11-22

ACTIVE_NOT_RECRUITING

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung CancerNCT04639245 · 2021-07-19

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell CancersNCT04388852 · 2020-08-20

ACTIVE_NOT_RECRUITING

Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid TumorsNCT04007744 · 2020-02-13

ACTIVE_NOT_RECRUITING

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid TumorsNCT03682289 · 2019-01-17

ACTIVE_NOT_RECRUITING

Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor MalignanciesNCT03590054 · 2018-08-20

INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological CancersNCT03071328 · 2018-01-08

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign DiseaseNCT01552434 · 2012-10-16

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract CancerNCT00942331 · 2009-07-15

Common interventions

Leading sponsors

M.D. Anderson Cancer Center3 Mayo Clinic3 Fred Hutchinson Cancer Center2 National Cancer Institute (NCI)2 Rahul Aggarwal2 Duke University1 Merck Sharp & Dohme LLC1 Northwestern University1 Nurix Therapeutics, Inc.1 Orion Biotechnology Polska Sp. z o.o.1 RayzeBio, Inc.1

Trial status mix

RECRUITING6

ACTIVE_NOT_RECRUITING5

COMPLETED3

TERMINATED2

NOT_YET_RECRUITING1

WITHDRAWN1

Phase mix

PHASE110

PHASE27

EARLY_PHASE12

NA1

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.